ARWR | tickerfilter.com

Fundamental analysis

64%

Profitability 47%

Dept financing 41%

Liquidity 50%

Performance 90%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.87%

1 Month

22.20%

3 Months

2.44%

6 Months

82.09%

1 Year

473.26%

2 Year

189.51%

Key data

Stock price

$69.25

P/E Ratio

44.58

DAY RANGE

$68.09 - $70.48

EPS

$1.60

52 WEEK RANGE

$12.44 - $76.76

52 WEEK CHANGE

$460.28

MARKET CAP

9.016 B

YIELD

N/A

SHARES OUTSTANDING

140.032 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

2.19

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,153,032

AVERAGE 30 VOLUME

$1,927,731

Company detail

CEO: Christopher R. Anzalone
Region: US
Website: arrowheadpharma.com
Employees: 400
IPO year: 1997

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.

ARWR - ARROWHEAD PHARMACEUTICALS, INC.